VYNE Therapeutics’ (VYNE) Buy Rating Reaffirmed at HC Wainwright

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $5.75 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 34.35% from the company’s previous close.

Separately, BTIG Research started coverage on shares of VYNE Therapeutics in a research report on Monday, November 18th. They set a “buy” rating and a $8.00 price objective on the stock.

VYNE Therapeutics Price Performance

Shares of VYNE stock opened at $4.28 on Monday. The firm has a market cap of $63.13 million, a P/E ratio of -4.98 and a beta of 1.30. VYNE Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $4.29. The stock’s 50-day moving average is $2.92 and its two-hundred day moving average is $2.29.

Institutional Trading of VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics accounts for 0.0% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 17th biggest position. Lynx1 Capital Management LP owned about 0.11% of VYNE Therapeutics at the end of the most recent quarter. Institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.